ReviewF1000Research2018
Human metapneumovirus - what we know now.
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 1 synthesis or guideline pooled it, 190 citations in OpenAlex.
- Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study.The Lancet. Global health · 2021Pooled it
- Trial
- RNAi-based therapeutics targeting the F gene in human metapneumovirus: An in-silico approach.Journal, genetic engineering & biotechnology · 2026Article
- Review
- Characteristics and Risk Factors Associated With Hospitalization and Severe Disease in Patients Aged ≥ 60 Years With Human Metapneumovirus Infection Over Three Consecutive Seasons (2021-2024) in Valladolid, Spain. The VALLAVIRUS Study.Influenza and other respiratory viruses · 2026Article
- Biosensors as transformative tools for multiplex detection of respiratory viral pathogens.Archives of microbiology · 2026Review
- Human Metapneumovirus G Protein Immunogenicity and Safety Explored via Carrier Protein Fusion.Tropical medicine and infectious disease · 2026Article
- A Review of Respiratory Infection Caused by the Human Metapneumovirus: Occurrence, Epidemiology, Pathogenesis, Public Health Outcomes, and Intervention Strategies.Health science reports · 2026Article
- Epidemiology of HMPV and Other Respiratory Viral Infections Among Outpatients, 2016-2022.Open forum infectious diseases · 2026Article
- Gut microbiota and serum metabolome in children with human metapneumovirus infection.Frontiers in immunology · 2026Article
- Human Metapneumovirus (HMPV): A comprehensive review of its virology, epidemiology, clinical features, and advances in diagnosis and prevention.Northern clinics of Istanbul · 2026Review
- Genotype turnover and global evolutionary dynamics of G gene duplication variants in human metapneumovirus: insights from prospective surveillance in Nantong, China, 2024-2025.Frontiers in microbiology · 2026Article
- Forging a global shield against HMPV: Uniting healthcare systems and community action to counter a silent respiratory epidemic.AIMS public health · 2026Review
- HMPV-TherResDB: Comprehensive human metapneumovirus (HMPV) database for sequence-structure annotations, vaccine resources, and therapeutics research.Virus research · 2026Article
- Clinical Impact of Polymicrobial Interactions in Human-Metapneumovirus-Infected Children: A Targeted Next-Generation Sequencing Based Retrospective Study.Infection and drug resistance · 2026Article
- The intersection between human metapneumovirus and the respiratory microbiome.Virology journal · 2025Review
- Designing a multi-epitope mRNA vaccine to combat human metapneumovirus based on consensus sequence using reverse vaccinology.Journal of computer-aided molecular design · 2025Article
- Advances in Human Metapneumovirus Research: Clinical Impact, Diagnostic Innovations, and Therapeutic Challenges.Pathogens (Basel, Switzerland) · 2025Review
- Repurposing SARS CoV 2 ligands identifies salvianolic acid C as potential antiviral candidate against human metapneumovirus through computational study.Scientific reports · 2025Article
- HMPV Virus Outbreak: First Review in Literature.Journal of pharmacy & bioallied sciences · 2025Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Human metapneumovirus (HMPV) is a leading cause of acute respiratory infection, particularly in children, immunocompromised patients, and the elderly. HMPV, which is closely related to avian metapneumovirus subtype C, has circulated for at least 65 years, and nearly every child will be infected with HMPV by the age of 5. However, immunity is incomplete, and re-infections occur throughout adult life. Symptoms are similar to those of other respiratory viral infections, ranging from mild (cough, rhinorrhea, and fever) to more severe (bronchiolitis and pneumonia). The preferred method for diagnosis is reverse transcription-polymerase chain reaction as HMPV is difficult to culture. Although there have been many advances made in the past 16 years since its discovery, there are still no US Food and Drug Administration-approved antivirals or vaccines available to treat HMPV. Both small animal and non-human primate models have been established for the study of HMPV. This review will focus on the epidemiology, transmission, and clinical manifestations in humans as well as the animal models of HMPV pathogenesis and host immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.